康泰生物：股东解除一致行动关系

Core Viewpoint - The company 康泰生物 (300601.SZ) announced the termination of the concerted action agreement between its controlling shareholder, Du Weimin, and other parties, which will not affect the company's governance structure or operations [1][2]. Group 1 - The termination of the concerted action agreement is set to take effect on February 6, 2026, and involves parties including Yuan Liping and several private equity funds managed by 博普资产 [1]. - The change in the concerted action relationship will not lead to any changes in the controlling shareholder or actual controller of the company [2]. - The parties involved will continue to comply with relevant laws and regulations regarding share reduction, and there are no differences in commitments before and after the termination [2]. Group 2 - The termination of the concerted action agreement is described as an optimization of corporate governance and is unrelated to any share reduction activities [2].